BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18208417)

  • 21. Clinical experience with the delivery of thawed and washed autologous blood cells, with an automated closed fluid management device: CytoMate.
    Lemarie C; Calmels B; Malenfant C; Arneodo V; Blaise D; Viret F; Bouabdallah R; Ladaique P; Viens P; Chabannon C
    Transfusion; 2005 May; 45(5):737-42. PubMed ID: 15847663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Large-capacity expanded cytoline-induced killer cells and its cytotoxic activity].
    Shi Y; Yu J; Cen X; Zhu P; Ma M
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2001 Mar; 18(1):94-6. PubMed ID: 11332127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
    Tam YK; Martinson JA; Doligosa K; Klingemann HG
    Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
    Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
    Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
    Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
    Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
    J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
    Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
    Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of tumor-dendritic cell fusion vaccines on the cytotoxicity of CIK/NK cells from cord blood].
    Li Y; Huang SL; Wu YF; Wei J; Meng Y; Zhou DH; Bao R
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):269-72. PubMed ID: 15949286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
    Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
    Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.
    Tran CA; Burton L; Russom D; Wagner JR; Jensen MC; Forman SJ; DiGiusto DL
    J Immunother; 2007 Sep; 30(6):644-54. PubMed ID: 17667528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
    Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
    Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.
    Sangiolo D; Martinuzzi E; Todorovic M; Vitaggio K; Vallario A; Jordaney N; Carnevale-Schianca F; Capaldi A; Geuna M; Casorzo L; Nash RA; Aglietta M; Cignetti A
    Int Immunol; 2008 Jul; 20(7):841-8. PubMed ID: 18469328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical evaluation of an automated closed fluid management device: Cytomate, for washing out DMSO from hematopoietic stem cell grafts after thawing.
    Calmels B; Houzé P; Hengesse JC; Ducrot T; Malenfant C; Chabannon C
    Bone Marrow Transplant; 2003 May; 31(9):823-8. PubMed ID: 12732892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of dendritic cells co-cultured with cytokine induced killer cells on cytotoxicity against drug resistant K562 cells].
    Chen BA; Li M; Sun ZY; Li CP; Gao C; Sun YY; Wang J; Fu Q; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):355-8. PubMed ID: 16185482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells.
    Jiang J; Xu N; Wu C; Deng H; Lu M; Li M; Xu B; Wu J; Wang R; Xu J; Nilsson-Ehle P
    Anticancer Res; 2006; 26(3B):2237-42. PubMed ID: 16821594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
    Introna M; Franceschetti M; Ciocca A; Borleri G; Conti E; Golay J; Rambaldi A
    Bone Marrow Transplant; 2006 Nov; 38(9):621-7. PubMed ID: 16980990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function.
    Lin SJ; Kuo ML
    Cytotherapy; 2008; 10(4):397-405. PubMed ID: 18574772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.